Sudeep Pharma’s initial public offering (IPO) entered its third and final day of bidding on November 25, continuing to attract strong investor interest. By the end of Day 2, the issue had already been subscribed to 5.09 times, indicating healthy demand across categories. Today marks the closing day for applications in the ₹895 crore public issue.

Contents

IPO Details: Price Band, Issue Size and Structure Use of Funds: Capital Expenditure and Corporate Needs GMP Declines to 15% on Final Day Subscription Status: IPO Booked 11.16x

The company had earlier raised ₹268.5 crore from anchor investors ahead of the IPO opening last week.

IPO Details: Price Band, Issue Size and Structure

The Sudeep Pharma IPO is priced in the range of ₹563 to ₹593 per share. The public issue comprises both a fresh issue and an offer for sale (OFS):

Fresh Issue: Shares worth ₹95 crore
Offer for Sale: Nearly 1.35 crore shares valued at ₹800 crore, offered by the promoters

The total issue size stands at ₹895 crore, and bidding concludes today.

Also Read: Reliance Industries Shares Hit 52-Week High as JPMorgan Turns Bullish on 2026 Outlook

Use of Funds: Capital Expenditure and Corporate Needs

From the fresh issue proceeds, the company plans to deploy ₹75.81 crore toward capital expenditure. This will be used for purchasing machinery for the production line at its Nandesari Facility 1 in Gujarat. The remaining funds will support general corporate purposes.

Sudeep Pharma operates as a technology-driven manufacturer of excipients and speciality ingredients supplying to the pharmaceutical, food, and nutrition sectors. The company positions itself as a contributor to the global healthcare ecosystem through its specialised product offerings.

GMP Declines to 15% on Final Day

The grey market premium (GMP) for Sudeep Pharma IPO fell today, indicating a moderation in near-term listing expectations. The GMP dipped to ₹86, compared to ₹20% earlier.

At the current GMP level, Sudeep Pharma shares are trading ₹86 above the upper end of the price band of ₹593. This signals a potential listing price of around ₹679, which translates to a 14.50% premium over the issue price.

Market watchers note that although the GMP has softened, it still indicates the possibility of a positive debut if sentiment holds.

Subscription Status: IPO Booked 11.16x

On the third day, subscription data indicates that the IPO is booked 11.16 times, reflecting strong participation from investors across categories. This comes after the issue had already received more than five bids by the end of Day 2.

The steady traction suggests that investors continue to show confidence in the company’s operations and future plans, despite the dip in GMP.

What to Watch Ahead?

With the bidding window closing today, all eyes now shift to the final subscription numbers, investor allocation, and the eventual listing performance. The volatility in GMP highlights the mixed sentiment in the broader market, but strong subscription figures signal sustained interest.

Investors tracking the Sudeep Pharma IPO can stay tuned for allocation status updates, listing price expectations, and further developments once the bidding concludes.

Click here to explore: Sudeep Pharma IPO